Beta Bionics, Inc. 8-K

What Happened

• Beta Bionics, Inc. (BBNX) held its 2026 Annual Meeting of Stockholders on May 21, 2026 (record date March 23, 2026). A quorum of 36,061,048 of 44,561,695 outstanding shares was represented.
• Stockholders elected two Class I directors — Sean D. Carney and Christy Jones — to terms expiring at the 2029 Annual Meeting. Vote totals: Sean D. Carney — 30,659,060 for, 608,992 withheld, 4,792,996 broker non-votes; Christy Jones — 25,865,542 for, 5,402,510 withheld, 4,792,996 broker non-votes.
• Stockholders ratified the Audit Committee’s selection of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (36,011,432 for; 41,527 against; 8,089 abstentions). No other proposals were voted on.

Key Details

• Meeting date: May 21, 2026; Record date: March 23, 2026.
• Shares outstanding at record date: 44,561,695; shares represented: 36,061,048.
• Director election votes: Carney — 30,659,060 for; Jones — 25,865,542 for.
• Auditor ratification vote: 36,011,432 for, 41,527 against, 8,089 abstain.

Why It Matters

• Election results confirm the company’s board composition through 2029 for these Class I seats, which affects corporate governance and oversight.
• Ratification of Ernst & Young as auditor confirms continuity in external financial review for fiscal 2026, important for financial reporting and investor confidence.
• The vote totals and presence of broker non-votes show shareholder participation levels and where shares were voted or left to brokers, useful context for governance outcomes.